In search of a treatment for Alzheimer's disease and potential immunonosuppresive therapeutic interventions.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Neuro - endocrinology letters

• Publication date

  2008-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 18766151
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics

  2009cited by this paper
• Aβ inhibits the proteasome and enhances amyloid and tau accumulation

  2008cited by this paper
• In Brief

  2007cited by this paper
• Neuroinflammation and regulation of glial glutamate uptake in neurological disorders

  2007cited by this paper
• Neurodegeneration and Alzheimer’s disease: the lesson from tauopathies

  2007cited by this paper
• NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies.

  2007cited by this paper
• Inhibitor of cyclooxygenase-2 protects against amyloid beta peptide-evoked memory impairment in mice.

  2007cited by this paper
• Hematopoietic Prostaglandin D Synthase and DP1 Receptor Are Selectively Upregulated in Microglia and Astrocytes Within Senile Plaques From Human Patients and in a Mouse Model of Alzheimer Disease

  2007cited by this paper
• Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease

  2007cited by this paper
• Inflammatory processes in Alzheimer's disease.

  2007cited by this paper
• Cerebrospinal fluid antimicroglial antibodies in Alzheimer disease: a putative marker of an ongoing inflammatory process.

  2007cited by this paper
• Immunity and neuronal repair in the progression of Alzheimer's disease: a brief overview.

  2007cited by this paper
• Microglial transplantation increases amyloid-beta clearance in Alzheimer model rats.

  2007cited by this paper
• Alzheimer's Disease: Progress in the Development of Anti-amyloid Disease-Modifying Therapies

  2007cited by this paper
• A beneficial role for IL-1 beta in Alzheimer disease?

  2007cited by this paper
• Immunotherapy against APP β-Secretase Cleavage Site Improves Cognitive Function and Reduces Neuroinflammation in Tg2576 Mice without a Significant Effect on Brain Aβ Levels

  2007cited by this paper
• Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations.

  2007cited by this paper
• Conformation-sensitive Antibodies against Alzheimer Amyloid-β by Immunization with a Thioredoxin-constrained B-cell Epitope Peptide*

  2007cited by this paper
• Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease.

  2007cited by this paper
• Glucocorticoids may initiate Alzheimer's disease: a potential therapeutic role for mifepristone (RU-486).

  2007cited by this paper
• Drug evaluation: (R)-flurbiprofen--an enantiomer of flurbiprofen for the treatment of Alzheimer's disease.

  2007cited by this paper
• Antibody-Mediated Clearance of Amyloid-β Peptide from Cerebral Amyloid Angiopathy Revealed by Quantitative In Vivo Imaging

  2007cited by this paper
• Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model

  2007cited by this paper
• Vaccination Strategies for Alzheimer’s Disease

  2007cited by this paper
• Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils.

  2007cited by this paper
• Antibody against C-terminal Abeta selectively elevates plasma Abeta

  2007cited by this paper
• Pro-inflammatory conditions promote neuronal damage mediated by Amyloid Precursor Protein and decrease its phagocytosis and degradation by microglial cells in culture.

  2007cited by this paper
• Intravenous immunoglobulin and Alzheimer's disease immunotherapy.

  2007cited by this paper
• Monoclonal antibodies that target pathological assemblies of Aβ

  2007cited by this paper
• Microglial activation and its implications in the brain diseases.

  2007cited by this paper
• Stimulation of endogenous neurogenesis by anti-EFRH immunization in a transgenic mouse model of Alzheimer's disease

  2007cited by this paper
• Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage.

  2007cited by this paper
• Vaccine development for Alzheimer's disease.

  2006cited by this paper
• Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein.

  2006cited by this paper
• A molecular link between the active component of marijuana and Alzheimer's disease pathology.

  2006cited by this paper
• Reduction of Soluble Aβ and Tau, but Not Soluble Aβ Alone, Ameliorates Cognitive Decline in Transgenic Mice with Plaques and Tangles*

  2006cited by this paper
• Human amyloid beta-induced neuroinflammation is an early event in neurodegeneration.

  2006cited by this paper
• Vaccination of Alzheimer's model mice with Aβ derivative in alum adjuvant reduces Aβ burden without microhemorrhages

  2006cited by this paper
• Immunotherapy for Alzheimer's disease

  2006cited by this paper
• Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets.

  2006cited by this paper
• Alzheimer's disease immunotherapy: From in vitro amyloid immunomodulation to in vivo vaccination

  2006cited by this paper
• Developing Novel Immunogens for an Effective, Safe Alzheimer’s Disease Vaccine

  2006cited by this paper
• In vivo evidence for microglial activation in neurodegenerative dementia

  2006cited by this paper
• Progression of disease and a remedy: causative role of macrophages and microglia: remedial effect of immunomodulatory and immunosuppressive therapies "in combination".

  2006cited by this paper
• Alzheimer's disease: Abeta, tau and synaptic dysfunction.

  2005cited by this paper
• Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation

  2005cited by this paper
• Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates.

  2005cited by this paper
• Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors.

  2005cited by this paper
• Tau phosphorylation in Alzheimer's disease: pathogen or protector?

  2005cited by this paper
• The role of inflammation in Alzheimer's disease.

  2005cited by this paper
• Glia and their cytokines in progression of neurodegeneration.

  2005cited by this paper
• Generation of anti-beta-amyloid antibodies via phage display technology towards Alzheimer's disease vaccination.

  2005cited by this paper
• Vascular consequences of passive Aβ immunization for Alzheimer's disease. Is avoidance of "malactivation" of microglia enough?

  2005cited by this paper
• Age- and sex-dependent development of adrenocortical hyperactivity in a transgenic mouse model of Alzheimer's disease.

  2004cited by this paper
• Microglia as a potential bridge between the amyloid beta-peptide and tau.

  2004cited by this paper
• Early Vitamin E supplementation in young but not aged mice reduces Aβ levels and amyloid deposition in a transgenic model of Alzheimer's disease

  2004cited by this paper
• Microglial Phagocytosis of Fibrillar β-Amyloid through a β1 Integrin-Dependent Mechanism

  2004cited by this paper
• Immunotherapy for Alzheimer's disease

  2004cited by this paper
• Therapeutic potential of oxidant mechanisms in Alzheimer’s disease

  2004cited by this paper
• IL-10 and glucocorticoids inhibit Abeta(1-42)- and lipopolysaccharide-induced pro-inflammatory cytokine and chemokine induction in the central nervous system.

  2003cited by this paper
• Degradation of beta-amyloid by proteolytic antibody light chains.

  2003cited by this paper
• Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic Aß42 by Inhibiting Rho

  2003cited by this paper
• Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho.

  2003cited by this paper
• Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity.

  2003cited by this paper
• Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains

  2003cited by this paper
• The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics

  2002cited by this paper
• Dietary intake of antioxidants and risk of Alzheimer disease.

  2002cited by this paper
• Increased CSF cortisol in AD is a function of APOE genotype

  2001cited by this paper
• Vitamin E suppression of microglial activation is neuroprotective

  2001cited by this paper
• Alzheimer Disease Therapeutics

  2001cited by this paper
• The interrelations of migraine, vertigo, and migrainous vertigo

  2001cited by this paper
• Fear recognition deficits after focal brain damage

  2000cited by this paper
• Inflammation and Alzheimer's disease.

  2000cited by this paper
• Patterns of brain activation in people at risk for Alzheimer's disease.

  2000cited by this paper
• Modulation of Alzheimer's beta-amyloid neurotoxicity by site-directed single-chain antibody.

  2000cited by this paper
• The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells.

  1999cited by this paper
• Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging

  1998cited by this paper
• Glial‐Neuronal Interactions in Alzheimer's Disease: The Potential Role of a ‘Cytokine Cycle’ in Disease Progression

  1998cited by this paper
• The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons.

  1996cited by this paper
• The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease.

  1996cited by this paper
• Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease.

  1996cited by this paper
• Stimulation of Cannabinoid Receptor CB1 Induces krox-24 Expression in Human Astrocytoma Cells (*)

  1995cited by this paper
• The FASEB Journal • Research Communication Oral

  year unknowncited by this paper

• syNthetic caNNabiNoids iN demeNtia with agitatioN: case studies aNd literature review

  2013cites this paper
• Activation of type-2 cannabinoid receptor inhibits neuroprotective and antiinflammatory actions of glucocorticoid receptor α: when one is better than two

  2013cites this paper
• Intravitreous delivery of the corticosteroid fluocinolone acetonide attenuates retinal degeneration in S334ter-4 rats.

  2010cites this paper
• Efficacy of structural homoloques and isomers of pralidoxime in reactivation of immobilised acetylcholinesterase inhibited with sarin, cyclosarin and soman.

  2009cites this paper